A total of 28 Avilanians are included in Phase III of the clinical trial to evaluate the effectiveness and safety of the neuroprotective drug NeuralCIM®, developed for the treatment of mild to moderate Alzheimer’s disease.

The Master of Science Thayde Trujillo Tirado, coordinator of this study in the province, informed this station that the evaluation of patients for their inclusion is still being carried out.

Multidisciplinary teams at the Roberto Rodríguez hospital, in the municipality of Morón, and Antonio Luaces Iraola, in the main city, determine compliance with the parameters for the investigation.

Currently, 12 clinical trials are underway in Ciego de Ávila, three of them with active inclusion of patients, all promoted by the Molecular Immunology Center (CIM).

In addition to the trial with NeuralCIM® in patients with amnestic variant Alzheimer’s, the evaluation of convalescents from COVID-19 who present pulmonary fibrosis or cardiovascular and renal sequelae prior to clinical diagnosis is performed.

Trujillo Tirado said that, in the case of NeuralCIM®, the evaluation and effectiveness of the drug is a new step closer to becoming a reality and that it offers hope to thousands of people afflicted with this type of dementia.